{"filings":[{"id":2105839,"accession_number":"0001140361-26-031672","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-08-06T20:06:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q2 2026 revenue drops 49% YoY to $41M; EPS $0.17 vs $0.49","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $37.9M in Q2 2026, down from $79.1M in Q2 2025; total revenues $41.0M vs $81.1M.","Net income $12.5M ($0.17 diluted EPS) vs $35.5M ($0.49) in prior year.","Delivered $24M IV TPOXX to US strategic national stockpile (final order under 19C contract) and $13M oral TPOXX to two international customers.","Special cash dividend of $0.60 per share declared March 26, paid April 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972684,"accession_number":"0001140361-26-024780","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-06-10T20:05:24+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"SIGA shareholders approve 6.5M share increase in 2010 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 38.8M for, 12.4M against, 20,559 abstain; broker non-votes 11.2M.","Plan amendment raises authorized shares from 8.5M to 15M.","All eight director nominees elected, including Jaymie A. Durnan and Harold E. Ford, Jr.","Ratification of PwC as auditor and advisory say-on-pay resolution both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90565,"accession_number":"0001140361-26-019538","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.","Operating loss $(5.3)M; net loss $(3.5)M or $(0.05) diluted EPS.","Expects $13M oral TPOXX delivery to Asia Pacific customer in Q2 and $26M IV TPOXX to US SNS by end of Q3 2026.","Signed exclusive license with Hikma MENA for TPOXX commercialization in MENA region in March 2026.","Declared special cash dividend $0.60/share in March 2026, paid April 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":6242580.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100199,"accession_number":"0001140361-26-011361","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SIGA declares special $0.60/share dividend payable April 23","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special one-time cash dividend of $0.60 per common share declared.","Record date for dividend is April 7, 2026.","Dividend payable on April 23, 2026.","Announced on March 26, 2026 via press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100198,"accession_number":"0001140361-26-008782","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.","Net income of $23.3M ($0.32 diluted EPS) vs $59.2M ($0.82) in 2024.","Q4 product sales fell to $2.2M from $79.8M; operating loss of $9.5M.","Received $13M international order for oral TPOXX in Jan 2026; delivery expected in 2026.","BARDA 19C contract added $27M in development funding for pediatric program and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116533,"accession_number":"0001140361-25-040775","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.","Net loss of $6.4M ($0.09 diluted loss per share) vs net income of $1.3M ($0.02) in Q3 2024.","Nine-month 2025 product revenues $85.8M, net income $28.7M ($0.40 EPS) vs $53.5M and $13.5M ($0.19) in 2024.","Year-to-date $53M oral TPOXX and $26M IV TPOXX delivered to U.S. SNS; $6M oral to international customer.","Special dividend of $0.60/share paid May 2025; BARDA contract added $27M development funding in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":90780818.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132986,"accession_number":"0001140361-25-028821","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales","Net income of $35.5M ($0.49 diluted EPS) versus $1.8M ($0.03) in Q2 2024; operating income $45.7M vs $1.1M","Gain on sale of aviation consultancy business to WMES joint venture of $43.0M in Q2 2025","BARDA 19C contract modified to add $27M in development funding during Q2, including $13M for pediatric program and $14M for manufacturing","Special cash dividend of $0.60 per share declared April 8, paid May 15, 2025; portfolio utilization improved to 88.3%"],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":88160818.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149542,"accession_number":"0001140361-25-022316","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"SIGA shareholders elect board, ratify auditor, approve officer liability amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; highest vote total 52.1M for John M. Keane; lowest 47.8M for Joseph W. Marshall.","Ratification of PricewaterhouseCoopers as auditor: 62.4M for, 1.6M against, 22.8K abstain.","Amendment to limit officer liability approved: 48.7M for, 4.3M against, 18.5K abstain.","Bylaws amended to designate Delaware Chancery Court as exclusive forum for state law claims and federal district courts for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149541,"accession_number":"0001140361-25-017954","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.","Outstanding SNS orders $94M as of March 31, 2025; expect delivery of $70M by end of Q3 2025, remainder in 2026.","Received $26M IV TPOXX order from U.S. Govt in March; contract modification added $14M for manufacturing support.","International sale of ~$6M in Q1; TPOXX received regulatory approval in Japan (as TEPOXX) in January 2025.","Special cash dividend of $0.60/share declared on April 8, payable May 15, 2025 to holders of record April 29."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7040815.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149540,"accession_number":"0001140361-25-012708","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SIGA declares special one-time dividend of $0.60/share payable May 15, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special one-time cash dividend of $0.60 per share declared on April 8, 2025.","Dividend payable on May 15, 2025 to holders of record on April 29, 2025.","No other significant news or financial results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168614,"accession_number":"0001140361-25-009163","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies appoints General John M. Keane to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gen. Keane appointed effective March 17, 2025; term expires at next annual meeting.","Granted fully vested options for 25,000 shares at $5.63 (closing price on appointment date).","Annual retainer of $45,000 (prorated) paid quarterly in arrears.","Board determined Keane meets Nasdaq independence requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168613,"accession_number":"0001140361-25-008092","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.","Net income $59.2M ($0.82 diluted EPS) vs $68.1M ($0.95) in 2023; operating income $70M.","Q4 product sales $79.8M, down from $115.7M in Q4 2023; Q4 net income $45.7M ($0.63 EPS).","Company has ~$70M of outstanding procurement orders entering 2025.","TPOXX received Japanese approval in Jan 2025; first African sale to Morocco in Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185727,"accession_number":"0001140361-24-049534","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SIGA Technologies amends bylaws to update stockholder nomination procedures and proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated bylaws effective Dec 10, 2024.","Updates advance notice provisions for stockholder nominations, incorporating SEC universal proxy rules (Rule 14a-19).","Stockholder list provisions updated to reflect Delaware law amendments.","New rule: stockholder soliciting proxies must use a proxy card color other than white.","Additional ministerial and clarifying changes made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185726,"accession_number":"0001140361-24-048907","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.","Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.","Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.","CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.","Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185725,"accession_number":"0001140361-24-045654","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.","Net income of $1.3M ($0.02 diluted EPS) vs net loss of $0.4M in Q3 2023.","Received $122M in procurement orders, including $112.5M from BARDA for oral TPOXX to the SNS.","Special cash dividend of $0.60/share paid April 2024, up $0.15 from prior year.","Exclusive license from Vanderbilt for preclinical monoclonal antibodies targeting orthopoxviruses."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":57250527.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185724,"accession_number":"0001140361-24-042883","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SIGA shifts CFO and CSO comp to equity-heavy mix; bonus targets cut from 100% to 50% of salary by 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Luckshire and CSO Hruby target annual bonus drops to 75% of base salary in 2025, then 50% from 2026 onward.","Equity grants rise to 50% of base salary in 2025, 75% in 2026, then 100% from 2027 onward.","Luckshire gets enhanced change-of-control severance: 2x (base + target bonus) plus 18 months COBRA.","Amendments effective October 1, 2024; 2024 annual bonus target remains at 100% of base salary.","Changes aim to better align officer incentives with long-term stockholder interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202294,"accession_number":"0001140361-24-041654","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies terminates EVP and CMO Dr. Jay Varma effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Varma terminated as EVP and Chief Medical Officer on September 23, 2024.","Termination was other than for cause, effective immediately.","His service on the Board of Directors automatically ended.","No replacement for Dr. Varma has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202293,"accession_number":"0001140361-24-041564","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.","No replacement or interim appointment announced for either the CMO role or board seat.","Company has not disclosed the reason for leave or expected duration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202292,"accession_number":"0001140361-24-037428","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.","Tecovirimat showed clinical benefit vs. placebo in patients treated ≤7 days from symptom onset and those with ≥100 lesions.","Safety profile comparable to placebo; consistent with prior studies over 15 years.","Four additional randomized trials (STOMP, UNITY, Platinum-CAN, EPOXI) are ongoing.","Trial hospitalized all patients, which may have reduced measured benefit vs. real-world settings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202291,"accession_number":"0001140361-24-035316","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.","Received $113M procurement order from U.S. government for oral TPOXX in July 2024 under BARDA contract.","Delivered $18M of IV TPOXX to U.S. SNS in Q2; $3M oral TPOXX to new ASEAN customer.","Paid special cash dividend of $0.60 per share on April 11, 2024, up $0.15 from prior year.","Amendment with Meridian gives SIGA control over international promotion of oral TPOXX effective June 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":47240746.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202290,"accession_number":"0001140361-24-033536","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA receives $113M US government procurement order for oral TPOXX","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.","Order builds on 2023 orders from U.S. government and 15 international customers for orthopoxvirus preparedness.","Project funded by BARDA and Strategic National Stockpile under contract 75A50118C00019.","CEO Diem Nguyen says order supports public health and shareholder returns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218390,"accession_number":"0001140361-24-030011","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SIGA stockholders elect nine directors and ratify PwC as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90.04% of shares represented at June 11, 2024 annual meeting.","All nine director nominees elected; Diem Nguyen received highest 'for' votes (50,834,176).","Ratification of PwC as auditor: 61,952,614 for, 1,879,362 against, 212,356 abstain.","Broker non-votes on director elections: 13,008,032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218389,"accession_number":"0001140361-24-024697","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.","Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).","Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.","Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.","Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":25429855.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218388,"accession_number":"0001140361-24-016900","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SIGA assumes primary responsibility for oral TPOXX promotion; Meridian retains limited rights in EU/UK/AU/JP/CH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Promotion Agreement effective June 1, 2024; SIGA takes over global advertising, promotion and sale of oral TPOXX.","Meridian retains non-exclusive rights only in European Economic Area, Australia, Japan, Switzerland and the UK.","Meridian receives reduced promotion fee: high single-digit percentage of collected proceeds from Territory sales.","Agreement has fixed term expiring May 31, 2026, with no automatic renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238315,"accession_number":"0001140361-24-012801","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Technologies reports 2023 product sales of $131M, pre-tax operating income $84M; declares $0.60 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.","Pre-tax operating income grew 96% to $83.6M; diluted EPS of $0.95 vs $0.46 in 2022.","Board declared special cash dividend of $0.60/share, up from $0.45 last year.","Fourth-quarter product sales surged to $115.7M, driven by $98M oral TPOXX delivery to U.S. SNS.","Over 25 countries ordered oral TPOXX in past two years; EU framework yielded $18M orders in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238314,"accession_number":"0001140361-24-003106","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.","Compensation includes $900K base salary, $450K 2024 bonus, $450K sign-on bonus, and equity grants valued at ~$3.15M.","Nguyen brings experience from Xalud Therapeutics (CEO), PPD (EVP biopharma), and Pfizer (global president, Americas Essential Health).","Employment agreement includes severance: 2x base salary for qualifying termination, 3x base plus bonus upon change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238313,"accession_number":"0001140361-24-000023","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SIGA extends CEO Gomez's transition to March 31, 2024 as successor search continues","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Phillip Louis Gomez III will remain CEO until March 31, 2024, or earlier upon successor's start.","Amendment extends prior end date from Jan 1, 2024; successor search is ongoing.","Gomez eligible for base salary and pro-rated 2024 annual bonus during extended period.","All other terms of July 2023 transition agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255801,"accession_number":"0001140361-23-051899","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q3 revenue $9.2M, net loss $0.4M; guides FY pre-tax income $90-100M on Q4 deliveries","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 total revenue $9.2M, down from $72.2M YoY; net loss $0.4M vs net income $33.0M.","Targeting Q4 deliveries: ~$113M oral TPOXX to U.S. stockpile, $15-18M international, $5M DoD, up to $15M IV TPOXX.","Full-year 2023 pre-tax operating income target $90-100M; any Q4 delays shift to Jan 2024.","European Commission signed joint procurement framework on Oct 23; initial EU orders ~$18M oral TPOXX.","YTD spent ~$43M on capital management: $0.45 special dividend and ~1.7M shares repurchased."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":23436361.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273231,"accession_number":"0001140361-23-042810","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SIGA appoints Dr. Jay K. Varma as EVP and Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Varma appointed EVP and CMO, effective Sept 6, 2023; continues as board member.","Annual base salary $750,000; guaranteed bonus of $750,000 for 2023 (pro-rated) and 2024.","Initial term through Dec 31, 2024, with automatic one-year renewals unless notice given.","Severance includes base salary continuation, pro-rata bonus, 12-month COBRA, and accelerated equity vesting on qualifying termination.","Dr. Varma previously served on board since Nov 2022; former professor at Weill Cornell and CDC role in NYC COVID response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273230,"accession_number":"0001140361-23-038566","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA posts Q2 2023 revenue of $5.9M, net loss $2.9M; guides FY2023 pre-tax operating income $90M-$100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $5.9M, down from $16.7M YoY; net loss $2.9M vs net income $2.0M; diluted EPS -$0.04.","In July 2023, U.S. government ordered ~$113M oral TPOXX and $25M IV TPOXX for strategic stockpile.","Company expects H2 2023 revenues of ~$113M from oral TPOXX delivery plus $30M-$45M from other customers.","Full year 2023 pre-tax operating income guided at $90M-$100M.","Year-to-date spent ~$43M on capital management: $0.45/share special dividend and 1.7M share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":14201190.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273229,"accession_number":"0001140361-23-036771","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Phillip Gomez to retire by Jan 1, 2024; will serve as consultant for 24 months at full base salary retainer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Phillip Gomez will continue as CEO until Jan 1, 2024 or until a successor starts; possible extension if critical to a material initiative.","After departure, Gomez will provide advisory services for 24 months and receive monthly retainer equal to 100% of his base salary.","No 2023 annual bonus unless employment extends beyond Jan 1, 2024; pro-rata bonus possible under automatic extension.","Non-compete and non-solicitation covenants extended through later of one year after departure or end of consulting period.","Amended and restated transition agreement supersedes prior agreement dated Jan 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273228,"accession_number":"0001140361-23-036629","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"U.S. Government exercises ~$138M procurement options for oral and IV TPOXX from SIGA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA contract options exercised: ~$113M oral TPOXX (delivery in 2023) and ~$25M IV TPOXX (delivery starts 2024).","Orders follow 2022 deliveries to 13 international customers and U.S. DoD; CEO notes growing global demand for orthopoxvirus preparedness.","Oral TPOXX fully deliverable in 2023; IV TPOXX delivery under prior order to be completed before starting this new IV order.","Contract supported by HHS/ASPR/BARDA and Strategic National Stockpile under Contract No. 75A50118C00019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290126,"accession_number":"0001140361-23-030049","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SIGA stockholders elect eight directors, ratify auditor, approve say-on-pay and three-year frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with majority support; Jaymie A. Durnan received 45.6M for, 5.7M withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2023: 60.7M for, 2.8M against, 68k abstain.","Non-binding advisory vote on executive compensation approved: 46.3M for, 5.0M against, 79k abstain.","Frequency of future advisory votes: 27.6M for three years, 23.5M for one year; board adopts three-year cycle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290125,"accession_number":"0001140361-23-022944","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 revenues $8.3M, net loss $0.9M; declares $0.45 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenues $8.3M vs $10.5M in Q1 2022; net loss $0.9M ($0.01 diluted loss per share).","Operating loss $2.1M, compared to $1.4M in prior-year quarter.","Special dividend of $0.45 per share declared, payable June 1, 2023 to holders of record May 16, 2023.","Repurchased 1.1M shares for $7.5M in Q1 2023.","CEO targeting ~$11M oral TPOXX deliveries to DoD and ~$113M to SNS in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":8323025.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290124,"accession_number":"0001140361-23-022855","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA declares special $0.45/share cash dividend payable June 1, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $0.45 per share declared by the Board of Directors.","Dividend payable on June 1, 2023 to shareholders of record as of May 16, 2023.","CEO Phil Gomez cites strong cash resources and balance sheet as rationale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311059,"accession_number":"0001140361-23-009759","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports FY2022 revenue $110.8M, net income $33.9M; international sales surge to $71M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenues $110.8M (down from $133.7M in 2021); net income $33.9M ($0.46 diluted EPS vs $0.91).","International product sales ~$71M from 12 new customers, up from $13M in 2021 and $3M in 2020.","DoD awarded contracts up to ~$18M for oral TPOXX; ~$7M delivered in 2022, first DoD procurement.","BARDA exercised options for ~$26M of IV TPOXX after FDA approval in May 2022.","Paid special dividend $0.45/share and repurchased ~1.8M shares for ~$13M in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311058,"accession_number":"0001140361-23-001826","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SIGA Technologies CEO Phil Gomez plans 2023 retirement; board launches CEO search","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Phil Gomez announced retirement in 2023; will remain CEO until successor starts.","Board searching for new CEO; Gomez to then serve as senior advisor for up to 30 days.","Post-transition, Gomez will provide consulting for 12 months at 50% of base rate.","Departure not due to disagreement; Transition Agreement signed Jan 13, 2023.","Gomez continues to receive compensation until Transition Date; non-competition covenants extended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329692,"accession_number":"0001140361-22-041490","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies appoints Harold Ford and Dr. Jay Varma to board effective Nov 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harold Ford and Jay Varma, MD appointed as directors effective November 10, 2022.","Each granted fully vested stock options for 25,000 shares at $9.27 per share.","Each to receive annual retainer of $45,000 prorated for remaining term.","Appointments extend through next annual stockholders meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329691,"accession_number":"0001140361-22-039829","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q3 2022 revenue surges to $72.2M from $4.8M YoY; net income of $33.0M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 total revenues $72.2M, compared to $4.8M in Q3 2021; net income $33.0M ($0.45 diluted EPS).","Nine-month revenues $99.4M (prior year $18.3M); net income $34.7M ($0.47 diluted EPS).","International orders drove ~$61M in Q3 deliveries; through Oct 31, ~$77M orders from 13 customers (12 new).","DoD awarded up to $10.7M new contract (Sep); total 2022 DoD contracts up to $18.1M for oral TPOXX.","BARDA exercised ~$26M procurement option for IV TPOXX (Aug); monkeypox clinical trials initiated in US, UK, DRC."],"consensus_eps_estimate":null,"consensus_eps_actual":0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":99417471.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347250,"accession_number":"0001140361-22-028809","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA receives BARDA $26M procurement option exercise for IV TPOXX; deliveries targeted for 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA exercises procurement options valued at approximately $26M for IV TPOXX under contract 19C.","This is the first procurement option exercise for IV TPOXX under the 19C contract.","Product deliveries of IV TPOXX are targeted for 2023.","Option also funds a post-marketing field study for IV TPOXX.","CEO highlights growing importance of broad orthopox response including monkeypox and smallpox."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347249,"accession_number":"0001140361-22-028201","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"SIGA Q2 revenue $16.7M (+92% YoY); special dividend; director resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $16.7M (up 92% YoY); net income $2.0M, diluted EPS $0.03 vs ($0.00).","Received ~$60M international oral TPOXX orders YTD from 10 jurisdictions, 9 new customers.","Declared special dividend $0.45/share; repurchased ~0.5M shares for $3.6M in Q2.","Director James Antal resigned July 31 for personal health reasons; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":27206345.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347248,"accession_number":"0001140361-22-025842","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA announces ~$28M in international orders for oral TPOXX amid monkeypox outbreak","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Orders include $26M from Canada (PHAC & DND) and $2M from two new jurisdictions (Europe, Asia Pacific).","Year-to-date international orders total ~$56M from six jurisdictions, five of them new customers.","Expects at least $26M in international deliveries by Sept 30, 2022; remaining delivery timing TBD.","Combined PHAC/DND orders for 2022 now ~$39M, including $13M previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363677,"accession_number":"0001140361-22-023248","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"SIGA shareholders approve charter amendment removing expired bankruptcy provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Charter amendment approved at June 14, 2022 annual meeting removes inoperative Bankruptcy Provisions tied to 2016 Plan of Reorganization.","All nine director nominees elected; votes ranged from 41.7M to 45.6M for, with 18.0M broker non-votes each.","Ratification of PwC as auditor passed with 63.6M for, 1.3M against; charter amendment passed with 46.9M for, 98k against.","89.8% of outstanding shares (65.0M of 72.4M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363676,"accession_number":"0001140361-22-017858","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.","First IV TPOXX sales to U.S. govt under BARDA contract: $7M delivered in Q1.","New Asia Pacific contract for ~$3M of oral TPOXX; PHAC contract increased $5M.","Board declared special dividend of $0.45/share, payable June 2 to holders of record May 17.","EMA approved oral tecovirimat for smallpox, monkeypox, cowpox, and vaccinia complications."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":10539299.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363675,"accession_number":"0001140361-22-017736","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA declares special cash dividend of $0.45 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend of $0.45 per share, payable June 2, 2022.","Record date is May 17, 2022.","CEO Phil Gomez cited strong balance sheet and confidence in business prospects.","Dividend reflects financial performance in 2020-2021 and optimism going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383461,"accession_number":"0001140361-22-011024","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies general counsel and CAO Robin Abrams resigns effective April 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robin E. Abrams resigned as General Counsel and CAO effective April 15, 2022.","Resignation is to pursue other opportunities; no disagreement with company.","No replacement named as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383460,"accession_number":"0001140361-22-007678","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.","Q4 2021 revenues $115.4M ($73.2M net income, $0.98 EPS) driven by $113M U.S. delivery of oral TPOXX.","International product sales $13M in 2021, up from $2M; EMA approved oral TPOXX in Jan 2022, Health Canada in Dec 2021.","SIGA repurchased ~3.8M shares for $26M in 2021 (~5% of shares outstanding); collaboration with Bioarchitech on immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401264,"accession_number":"0001140361-21-041838","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SIGA Technologies amends bylaws; removes 2016 Reorganization Plan provisions, adds majority-vote amendment requirement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated bylaws effective Dec. 9, 2021.","Removed provisions related to 2016 Plan of Reorganization that were no longer applicable.","Updated rules on uncertificated shares of stock.","Shareholder vote to amend bylaws now requires majority of outstanding capital stock entitled to vote.","Changes are ministerial, clarifying, and conforming in nature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401263,"accession_number":"0001140361-21-036567","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q3 revenue drop to $4.8M, net loss of $3.1M; secures $113M BARDA order for Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $4.8M in Q3 2021 vs $44.3M in Q3 2020; net loss $3.1M ($0.04 diluted loss) vs net income $24.2M ($0.31 diluted EPS).","Nine months 2021: revenues $18.3M, net loss $3.8M ($0.05 diluted loss) vs prior year revenues $87.2M, net income $36.2M ($0.45 diluted EPS).","BARDA exercised procurement option for oral TPOXX worth ~$113M; delivery targeted for Q4 2021, nearly 30% delivered in October.","Board authorized new $50M share repurchase program through Dec 2023; repurchased 1.1M shares for $7.1M in Q3.","International sales nine months $13M, >4x increase vs 2020; working on new foreign order similar to Canada initial orders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":18313206.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420217,"accession_number":"0001140361-21-031376","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2021-09-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DoD intends to negotiate sole-source contract with SIGA for TPOXX; size and timing not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["DoD publicly disclosed intent to negotiate a firm fixed-price sole-source contract for TPOXX.","SIGA believes initial order likely will be for a limited quantity of TPOXX.","No assurance that SIGA will successfully negotiate the contract or its terms.","SIGA continues discussions with DoD and other U.S. agencies on TPOXX stockpiles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-15T23:59:59+00:00|420217"}